Inhaled iloprost in pulmonary arterial hypertension

Annals of Pharmacotherapy

Volumn 39, Issue 7-8, 2005, Pages 1265-1274

  Baker, Stacey E ^a   Hockman, Rebecca Haynes ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Iloprost; Inhaled; Prostacyclin; Pulmonary hypertension

Indexed keywords

BOSENTAN; DOBUTAMINE; ILOPROST; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; SILDENAFIL; TOLAFENTRIN; UNCLASSIFIED DRUG; VASODILATOR AGENT;

AEROSOL; BONE PAIN; BURNING SENSATION; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG METABOLISM; DRY SKIN; FLU LIKE SYNDROME; FLUSHING; GINGIVITIS; HEADACHE; HEMODYNAMICS; HUMAN; HYPERSENSITIVITY; HYPOTENSION; JAW PAIN; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SYNCOPE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; VASODILATATION; VERTIGO;

ADMINISTRATION, INHALATION; ADULT; CHEMISTRY, PHARMACEUTICAL; CHILD; CLINICAL TRIALS; COSTS AND COST ANALYSIS; DRUG THERAPY, COMBINATION; EPOPROSTENOL; HUMANS; HYPERTENSION; ILOPROST; MEDLINE; NITRIC OXIDE; VASODILATOR AGENTS;

EID: 21744461765     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E575     Document Type: Review

References (71)

1. Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126(suppl)-.4S-6S.
2. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336: 111-7.
3. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
4. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126(suppl):14S-34S.
5. Abenhaim L, Monde Y, Brenot F, Rich S, Benichou J, Kurz X. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-16.
6. Rubin LJ. Primary pulmonary hypertension. Chest 1993;104:236-50.
7. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004:126(suppl):35S-62S.
8. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-9.
9. Package insert. Remodulin (treprostinil sodium). Research Triangle Park, NC: United Therapeutics, November 2004.
10. Package insert. Tracleer (bosentan). South San Francisco, CA: Actelion Pharmaceuticals, October 2004.
11. CoTherix. Products & pipeline, www.cotherix.com/ct/products (accessed 2004 Oct 19).
12. Goldsmith DR, Wagstaff AJ. Inhaled iloprost in primary pulmonary hypertension. Drugs 2004;64:763-73.
13. Barst RJ. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin. Heart 1997;77:299-301.
14. Yanagisawa M. The endothelin system: a new target for therapeutic intervention (editorial). Circulation 1994;89:1320-2.
15. Wilkens H, Bauer M, Forestier N, Konig J, Eichler A, Schneider S, et al. Influence of inhaled iloprost on transpulmonary gradient of big endothelin in patients with pulmonary hypertension. Circulation 2003;107:1509-13.
16. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214-21.
17. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159: 1925-32.
18. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002;26:194-201.
19. Beghetti M, Reber G, de Moerloose P, Vadas L, Chiappe A, Spahr-Schopfer I, et al. Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation. Eur Respir J 2002;19:518-24.
20. Wiedemann R, Ghofrani A, Weissmann N, Schermuly R, Quanz K, Grimminger F, et al. Atrial natriuretic peptide in severe primary and non-primary pulmonary hypertension. J Am Coll Cardiol 2001;38:1130-6.
21. Rose F, Hattar K, Gakisch S, Grimminger F, Olschewski H, Seeger W, et al. Increased neutrophil mediator release in patients with pulmonary hypertension -suppression by inhaled iloprost. Thromb Haemost 2003;90: 1141-9.
22. Olschewski H, Rohde B, Behr J, Ewert R, Gessler J, Ghofrani A, et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 2003;124:1294-304.
23. Grant SM, Goa KL. Iloprost: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 1992;43:889-924.
24. The European Agency for the Evaluation of Medicinal Products. Ventavis: summary of product characteristics, www.emea.eu.int (accessed 2004 Oct 18).
25. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9.
26. Olschewski H, Ghofrani A, Schmehl T, Winkler J, Wilkens H, Hoper MM, et al. Inhaled iloprost to treat severe pulmonary hypertension: an uncontrolled trial. Ann Intern Med 2000;132:435-43.
27. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetther E, Niedermeyer J, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000;342:1866-70.
28. Machherndl S, Kneussl M, Baumgartner H, Schneider B, Petkov V, Schenk P, et al. Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur Respir J 2001;17:8-13.
29. Wensel R, Opitz C, Ewert R, Bruch L, Kleber XF. Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension. Circulation 2000;101:2388-92.
30. Blumberg F, Riegger GA, Pfeifer M. Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise. Chest 2002;121:1566-71.
31. Opitz CF, Wensel R, Ewert R. Preserved long-term efficacy of iloprost inhalation therapy over 2 years in patients with primary pulmonary hypertension (abstract). J Am Coll Cardiol 2000;35(suppl A):286A.
32. Ewert R, Wensel R, Opitz C. Aerosolized iloprost for primary pulmonary hypertension (letter). N Engl J Med 2000;343:1421-2.
33. Higenbottam TW, Butt AY, Dinh-Xaun AT, Takao M, Cremona G, Akamine S. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 1998;79:175-9.
34. Higenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L. Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998;80:151-5.
35. Olschewski H, Walmrath D, Schermuly R, Ghofrani HA, Grimminger F, Seegar W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996;124:820-4.
36. Opitz CF, Wensel R, Bettmann M, Schaffarczyk R, Linscheid M, Hetzer R, et al. Assessment of the vasodilator response in primary pulmonary hypertension. Eur Heart J 2003;24:356-65.
37. Schenk P, Petkov V, Madl C, Kramer L, Kneussl M, Ziesche R, et al. Aerosolized iloprost therapy could not replace long-term IV epoprostenol (prostacyclin) administration in severe pulmonary hypertension. Chest 2001;119:296-300.
38. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol 2000;35:176-82.
39. Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolbe T, Behr J. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest 2004;125:580-6.
40. Petkov V, Ziesche R, Mosgoeller W, Schenk P, Vonbank K, Stiebellenner L, et al. Aerosolized iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment. Thorax 2001;56:734-6.
41. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218-22.
42. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002: 136:515-22.
43. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, et al. Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med 2002; 30:2489-92.
44. Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003;22:330-4.
45. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003;42:158-64.
46. National Institutes of Health. A study to evaluate the safety and pilot efficacy of iloprost inhaled solution as add-on therapy with bosentan in subjects with pulmonary arterial hypertension. www.clinicaltrials.gov (accessed 2004 Aug 24)
47. Rolla G, Colagrande P, Brussino L, Bucca C, Bertero MT, Caligaris-Cappio F. Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis with pulmonary hypertension. Lancet 1998;351:1491-2.
48. Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999;160:600-7.
49. Launay D, Hachulla E, Matron PY, Goullard L, Onimus T, Robin S, et al. Aerosolized iloprost in CREST syndrome related pulmonary hypertension. J Rheumatol 2001;28:2252-6.
50. Sablotzki A, Hentschel T, Gruenig E, Schubert S, Friedrich I, Muhling J, et al. Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance. Eur J Cardiothorac Surg 2002;22:746-52.
51. Sablotzki A, Czeslick E, Gruenig E, Friedrich I, Schubert S, Borgermann J, et al. First experiences with the stable prostacyclin analog iloprost in the evaluation of heart transplant candidates with increased pulmonary vascular resistance. J Thorac Cardiovasc Surg 2003;125:960-2.
52. Sablotzki A, Czeslick E, Schubert S, Friedrich I, Muhling J, Dehne MG, et al. Iloprost improves hemodynamics in patients with severe chronic cardiac failure and secondary pulmonary hypertension. Can J Anaesth 2002;49:1076-80.
53. Rex S, Busch T, Vettelschoss M, de Rossi L, Rossaint R, Buhre W. Intraoperative management of severe pulmonary hypertension during cardiac surgery with inhaled iloprost. Anesthesiology 2003;99:745-7.
54. Theodoraki K, Rellia P, Thanopoulos A, Tsourelis L, Zarkalis D, Sfyrakis P, et al. Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass. Can J Anaesth 2002;49:963-7.
55. Langer F, Wilhelm W, Tscholl D, Schramm R, Lausberg H, Wendler O, et al. Intraoperative inhalation of the long-acting prostacyclin analog iloprost for pulmonary hypertension. J Thorac Cardiovasc Surg 2003; 126:874-5.
56. Alp S, Schlottmann R, Bauer TT, Schmidt WE, Bastian A. Long-time survival with HIV-related pulmonary arterial hypertension: a case report. AIDS 2003;17:1714-5.
57. Ghofrani HA, Friese G, Discher T, Olschewski H, Schermuly RT, Weissmann N, et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J 2004;23:321-6.
58. Leuchte HH, Baumgartner RA, Behr J. Treatment of severe pulmonary hypertension with inhaled iloprost (letter). Ann Intern Med 2003;139: 306.
59. Beghetti M, Berner M, Rimensberger PC. Long term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusion. Heart 2001;86:e10.
60. Beghetti M, Nicod L, Barazzone-Argiroffo C, Rimensberger PC. New combined treatments avoided transplantation in a child with severe pulmonary hypertension. Heart 2004;90:154.
61. Emmel M, Keuth B, Schickendantz S. Paradoxical increase of pulmonary vascular resistance during testing of inhaled iloprost. Heart 2003;90:e2.
62. Muller M, Scholz S, Kwapisz M, Akinturk H, Thul J, Hempelmann G. Use of inhaled iloprost in a case of pulmonary hypertension during pediatric congenital heart surgery. Anesthesiology 2003;99:743-4.
63. Wittwer T, Pethig K, Struber M, Hoeper M, Hamnger W, Haverich A, et al. Aerosolized iloprost for severe pulmonary hypertension as a bridge to heart transplantation. Ann Thorac Surg 2001;71:1004-6.
64. Wittwer T, Franke U, Wahlers T. Impact of aerosolized prostacyclin analog for severe pulmonary hypertension in thoracic organ transplantation (letter). J Thorac Cardiovasc Surg 2002;124:211-3.
65. Rimensberger PC, Spahr-Schopfer I, Berner M, Jaeggi E, Kalangos A, Friedli B, et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation 2001; 103:544-8.
66. Hallioglu O, Dilber E, Celiker A. Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. Am J Cardiol 2003; 92:1007-9.
67. Package insert. Flolan (epoprostenol). Research Triangle Park, NC: GlaxoSmithKline, July 2001.
68. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
69. McCrory DC, Lewis SZ. Methodology and grading for pulmonary hypertension evidence review and guideline development. Chest 2004; 126(suppl):11S-3S.
70. Highland KB, Strange C, Mazur J, Simpson KN. Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest 2003;124:2087-92.
71. Package insert. Ventavis (iloprost). San Francisco: CoTherix. www. cotherix.com/ct/ventavis (accessed 2005 Jan 5).